drugset / Trial / NCT01055795
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to test the safety of three study drugs, bevacizumab (Avastin™), Everolimus (Afinitor™) and LBH589 (Panobinostat) when they are given together. It is hoped this study drug combination might lead to a greater decrease the in size of the cancer and/or slow down how fast the cancer is growing compared to when these drugs are given alone. Subjects will be enrolled at Duke University Medical Center (DUMC).
Timeline
- Start
- 2010-03
- Primary completion
- 2011-08
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Everolimus | Small molecule | — | Oral |
| Subject | Panobinostat | Small molecule | — | Oral |